 BARCELONA, Spain, April 2, 2021 PRNewswire -- Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing peoples health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin ITAC clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH, did not meet its primary endpoints with statistically significant results. The company will continue to move forward with its work on more than 20 research initiatives to find potential treatment options for different stages of COVID-19. 